<DOC>
	<DOCNO>NCT00676728</DOCNO>
	<brief_summary>The purpose study explore safety , pharmacokinetic ( body medication ) , pharmacodynamic ( medication body ) , activity JNJ-26481585 patient advance refractory leukemia myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>A Study Histone-deacetylase Inhibitor JNJ-26481585 Patients With Advanced Refractory Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , Phase 1 dose escalation , 2-part study ( Part I Part II ) . In Part I study , Maximum Tolerated Dose ( MTD ) define high dose observe incidence dose limit toxicity ( DLT ) 1 6 patient , determine use rapid escalation ( Stage 1 ) follow conventional escalation ( Stage 2 ) . In Stage 1 , least 2 patient enrol dose level ; dose increment 100 % apply . In Stage 2 , least 3 patient enrol dose level dose increment 20-50 % implement . Decisions dose escalation de-escalation , change time pharmacokinetic/pharmacodynamic sampling , exploration alternative schedule make Study Evaluation Team ( SET ) , consist principal investigator , medical monitor , 1 sponsor 's clinical pharmacologist . Part II study expansion phase , begin MTD determined Part I additional cohort patient MDS enrol explore safety activity JNJ 26481585 patient MDS . The start dose patient enrol Part II study MTD establish Part I . Depending outcome , SET may decide continue MTD dose , dose-de-escalate next low level ( 25 50 % decrement MTD ) . The cohort MDS expand consist 16 evaluable patient . Safety evaluate throughout study include evaluation adverse event clinical laboratory test , electrocardiogram ( ECG ) , vital sign , 24 hour Holter ECG , physical examination , Eastern Cooperative Oncology Group performance status Multiple Gated Acquisition scan echocardiography .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histologically cytologically confirm advanced refractory acute myeloid leukemia , acute lymphocytic leukemia , chronic myeloid leukemia blast phase , refractory chronic lymphocytic leukemia , myelodysplastic syndrome , chronic myelomonocytic leukemia For Part II , patient myelodysplastic syndrome Eastern Cooperative Oncology Group Performance Status Score 0 , 1 2 Left Ventricular Ejection Fraction great equal 50 % Negative hepatitis B , C human immunodeficiency virus ( HIV ) test within last 3 month Adequate liver kidney function Known suspect involvement central nervous system Chemotherapy ( nitrosoureas mitomycin C within 6 week ) , radiotherapy , immunotherapy treatment investigative agent within 3 week study drug administration ( except hydroxyurea stop least 24 hour prior first dose ) Unstable angina myocardial infarction within precede 12 month ; congestive heart failure Poorly control hypertension diabetes , ongoing active infection psychiatric illness Receiving medication know risk cause QTc prolongation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Advanced Refractory Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>JNJ 26481585</keyword>
	<keyword>Histone-Deacetylase Inhibitor</keyword>
	<keyword>Advanced Leukemia</keyword>
	<keyword>Refractory Leukemia</keyword>
</DOC>